VBI Vaccines Inc. (NASDAQ:VBIV) shares, rose in value, with the stock price down by -11.18% to the previous day’s close as strong demand from buyers drove the stock to $0.67.
Actively observing the price movement in the last trading, the stock closed the session at $0.75. The value of beta (5-year monthly) was 1.91. Referring to stock’s 52-week performance, its high was $5.90, and the low was $0.45. On the whole, VBIV has fluctuated by 14.97% over the past month.
With the market capitalization of VBI Vaccines Inc. currently standing at about $15.83 million, investors are eagerly awaiting this quarter’s results, scheduled for Apr 05, 2024 – Apr 09, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.22, which is expected to increase to -$0.17 for fiscal year -$6.59 and then to about -$0.82 by fiscal year 2024. Data indicates that the EPS growth is expected to be -1,397.70% in 2024, while the next year’s EPS growth is forecast to be 87.60%.
Analysts have estimated the company’s revenue for the quarter at $5.36 million, with a low estimate of $5.36 million and a high estimate of $5.36 million. According to the average forecast, sales growth in current quarter could jump up 1,729.40%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2024, the company’s y-o-y revenues would reach $13.19 million, representing an increase of 1,119.00% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that VBIV’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a Hold.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of VBIV currently trading nearly 11.61% and 8.41% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 58.30, while the 7-day volatility ratio is showing 13.42% which for the 30-day chart, stands at 7.67%. Furthermore, VBI Vaccines Inc. (VBIV)’s beta value is 1.88, and its average true range (ATR) is 0.05.
A comparison of VBI Vaccines Inc. (VBIV) with its peers suggests the former has fared considerably weaker in the market. VBIV showed an intraday change of -11.18% in last session, and over the past year, it shrunk by -92.58%%.
Data on historical trading for VBI Vaccines Inc. (NASDAQ:VBIV) indicates that the trading volumes over the past 10 days have averaged 0.72 million and over the past 3 months, they’ve averaged 227.39K. According to company’s latest data on outstanding shares, there are 23.69 million shares outstanding.
Nearly 5.94% of VBI Vaccines Inc.’s shares belong to company insiders and institutional investors own 12.26% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.3 million shares as on Mar 15, 2024, resulting in a short ratio of 1.81. According to the data, the short interest in VBI Vaccines Inc. (VBIV) stood at 1.28% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 0.37 million. The stock has risen by 13.74% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VBIV stock heading into the next quarter.
